Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$17.69
-0.4%
$18.18
$16.10
$42.47
$2.22B0.682.34 million shs2.09 million shs
ChromaDex Co. stock logo
CDXC
ChromaDex
$6.16
$2.31
$9.18
$611.50M2.21824,951 shs554,788 shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$43.50
$40.88
$31.42
$58.26
$2.78B1.24382,410 shs240,424 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$34.64
-3.5%
$33.73
$27.12
$60.90
$2.08B2.38970,850 shs1.49 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%-6.05%+1.43%-27.08%-53.53%
ChromaDex Co. stock logo
CDXC
ChromaDex
0.00%0.00%0.00%0.00%+188.10%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.00%-1.61%+11.74%+7.20%+13.19%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%+3.34%+22.58%-22.92%-32.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
4.6948 of 5 stars
4.33.00.04.43.22.50.6
ChromaDex Co. stock logo
CDXC
ChromaDex
2.6757 of 5 stars
3.50.00.04.00.60.01.9
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
1.2272 of 5 stars
3.50.00.00.00.62.50.0
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.098 of 5 stars
4.41.00.04.42.20.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.62
Moderate Buy$40.05126.41% Upside
ChromaDex Co. stock logo
CDXC
ChromaDex
3.00
Buy$9.03∞ Upside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
3.00
Buy$78.7180.95% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4045.50% Upside

Current Analyst Ratings Breakdown

Latest CDXC, APLS, TWST, and MLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$67.00
6/2/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$26.00 ➝ $29.00
5/22/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$49.00 ➝ $41.00
5/19/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$61.00
5/14/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$30.00 ➝ $20.00
5/13/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$78.00 ➝ $80.00
5/13/2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
5/9/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$75.00 ➝ $52.00
5/9/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$41.00 ➝ $23.00
5/8/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$21.00 ➝ $18.00
5/8/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$28.00 ➝ $20.00
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$781.37M2.85N/AN/A$1.84 per share9.61
ChromaDex Co. stock logo
CDXC
ChromaDex
$99.60M0.00N/AN/A$0.38 per share0.00
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$7.09 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.63N/AN/A$8.07 per share4.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$197.88M-$1.79N/AN/AN/A-28.83%-99.19%-25.35%7/30/2025 (Estimated)
ChromaDex Co. stock logo
CDXC
ChromaDex
-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$118.94M-$2.30N/AN/AN/AN/A-30.81%-28.40%8/6/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)

Latest CDXC, APLS, TWST, and MLTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.76-$0.63+$0.13-$0.63N/AN/A
5/7/2025Q1 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
ChromaDex Co. stock logo
CDXC
ChromaDex
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.76
4.08
3.62
ChromaDex Co. stock logo
CDXC
ChromaDex
N/A
2.95
2.35
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.18
21.11
21.11
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
ChromaDex Co. stock logo
CDXC
ChromaDex
15.41%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
6.80%
ChromaDex Co. stock logo
CDXC
ChromaDex
9.64%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
12.05%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770125.68 million117.14 millionOptionable
ChromaDex Co. stock logo
CDXC
ChromaDex
12077.75 million69.02 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
264.01 million56.30 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$17.69 -0.07 (-0.39%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$17.68 -0.01 (-0.06%)
As of 06/20/2025 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

ChromaDex stock logo

ChromaDex NASDAQ:CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$43.50 0.00 (0.00%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$43.52 +0.02 (+0.05%)
As of 06/20/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$34.64 -1.25 (-3.48%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$35.43 +0.79 (+2.28%)
As of 06/20/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.